Processa Pharmaceuticals (PCSA) Capital Expenditures (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Capital Expenditures came in at $500000.0 in Q1 2026, up 35639.81% quarter-over-quarter from $1399.0 in Q1 2015.
Powered by 
Analysis
Processa Pharmaceuticals (PCSA) Capital Expenditures (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has reported Capital Expenditures for 5 consecutive years, with $500000.0 the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $500000.0; the trailing twelve-month figure through Jun 2026 stood at $500000.0 (changed N/A YoY), and the FY2025 full-year result was $850000.0, up 26102.22% from the prior year.
- Capital Expenditures grew to $500000.0 in Q1 2026 per PCSA's latest filing, from $1399.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $500000.0 in Q1 2026 and bottomed at $500000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -321.00 Mn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 533.00 Mn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | 2.29 Mn |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 12.41 Mn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 108.00 Mn |
| 10 | Processa Pharmaceuticals | 5.75 Mn | 5.75 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 500,000.00 |
| Mar 31, 2015 | 1,399.00 |
| Dec 31, 2014 | -14,712.00 |
| Sep 30, 2014 | 9,947.00 |
| Jun 30, 2014 | 2,000.00 |
| Mar 31, 2014 | 13,772.00 |
| Dec 31, 2013 | 1.00 |
| Sep 30, 2013 | 20,341.00 |
| Jun 30, 2013 | 1,056.00 |
| Mar 31, 2013 | 6,276.00 |
| Dec 31, 2012 | 14,376.00 |
| Sep 30, 2012 | 244,273.00 |